Skip to main content

Table 3 Comparison of different categorization methods for predicting event-free survival at 2 years in patients alive and event free at 6 months (n = 76)

From: Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

Follow-up time for subpopulation predicted to progress

N (above, below) threshold or (slow, fast) response

Correctly classified,%

Positive predictive value,%

Negative predictive value,%

3 months

    

  > 10% BCR-ABL

32, 44

67.1

81.8

46.9

  > 1% BCR-ABL

51, 25

52.6

84.0

37.3

  > 0.1% BCR-ABL (MMR)

63, 13

44.7

92.3 *

34.9

6 months

    

  > 10% BCR-ABL

26, 50

75.0

84.0

57.7

  > 1% BCR-ABL

38, 38

64.5

84.2

44.7

  > 0.1% BCR-ABL (MMR)

50, 26

56.6

88.5

40.0

 Slow (monophasic) responders

27, 49

77.6 *

86.0

61.5 *

  1. Abbreviation: MMR = major molecular response.
  2. * The number in bold indicates the highest score for that column.